Esperion Therapeutics Stock Alpha and Beta Analysis
| ESPR Stock | USD 1.86 0.01 0.53% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Esperion Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Esperion Therapeutics over a specified time horizon. Remember, high Esperion Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Esperion Therapeutics' market risk premium analysis include:
Beta (1.02) | Alpha (0.15) | Risk 5.53 | Sharpe Ratio (0.05) | Expected Return (0.27) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Esperion |
Esperion Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Esperion Therapeutics market risk premium is the additional return an investor will receive from holding Esperion Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Esperion Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Esperion Therapeutics' performance over market.| α | -0.15 | β | -1.02 |
Esperion Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Esperion Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Esperion Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Esperion Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Esperion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Esperion Therapeutics shares will generate the highest return on investment. By understating and applying Esperion Therapeutics stock market price indicators, traders can identify Esperion Therapeutics position entry and exit signals to maximize returns.
Esperion Therapeutics Return and Market Media
The median price of Esperion Therapeutics for the period between Tue, Nov 19, 2024 and Mon, Feb 17, 2025 is 2.21 with a coefficient of variation of 19.2. The daily time series for the period is distributed with a sample standard deviation of 0.45, arithmetic mean of 2.32, and mean deviation of 0.31. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 197 shares by Warren Eric of Esperion Therapeutics at 2.165 subject to Rule 16b-3 | 11/19/2024 |
2 | Esperion Announces New Drug Submissions in Canada for NEXLETOL and NEXLIZET Treatments to Reduce LDL-C and Cardiovascular Risk | 12/02/2024 |
3 | Esperion Announces 210 Million Convertible Debt Financing | 12/13/2024 |
4 | Disposition of 12447 shares by Sheldon Koenig of Esperion Therapeutics at 2.466 subject to Rule 16b-3 | 12/17/2024 |
5 | Esperion reinstated with a Neutral at Goldman Sachs ESPR | 12/18/2024 |
6 | ESPR - Esperion Therapeutics, Inc. Latest Stock News Market Updates - StockTitan | 12/20/2024 |
7 | Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference | 01/02/2025 |
8 | Ardelyx Moves 16.0 percent Higher Will This Strength Last | 01/14/2025 |
9 | Disposition of 123 shares by Warren Eric of Esperion Therapeutics at 2.26 subject to Rule 16b-3 | 01/17/2025 |
10 | Esperion Therapeutics Buy Rating Reiterated at HC Wainwright | 01/23/2025 |
11 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 | 02/13/2025 |
About Esperion Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Esperion or other stocks. Alpha measures the amount that position in Esperion Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 1.17 | 1.36 | 1.23 | 0.77 | Days Of Inventory On Hand | 476.45 | 553.6 | 636.63 | 1.2K |
Esperion Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Esperion Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Esperion Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Esperion Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Esperion Therapeutics. Please utilize our Beneish M Score to check the likelihood of Esperion Therapeutics' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Esperion Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.